Industry Outlook: Healthcare & Life Sciences — Week of August 31, 2026

Market Outlook

• Record retrieval acceleration signals data liquidity race. Datavant’s new platform promising to cut medical record retrieval from days to hours highlights how payers, CROs, and health systems are converging on faster data liquidity. For CTOs, this is a clear signal that FHIR-native, API-first exchange and scalable consent management will be table stakes for participation in payer contracts, clinical trials, and value-based care networks.
• AI behavioral health funding continues to climb. Onos Health’s 17 million dollar raise for an AI-powered behavioral health platform shows capital is still flowing into targeted, outcomes-focused digital care rather than broad telehealth plays. Engineering teams in virtual care and digital therapeutics should expect higher expectations on measurable clinical outcomes, integration with EHRs, and evidence that models perform equitably across vulnerable populations.
• Employer cost pressure will reshape digital health demand. Business Group on Health projects a 9.2 percent rise in employer healthcare costs in 2027, which intensifies demand for solutions that cut total cost of care, not just improve experience. CTOs at vendors should anticipate sharper scrutiny of ROI, while provider and payer CTOs should prioritize analytics and care management tools that directly target chronic disease, specialty drugs, and preventable admissions.

Discussion: Watch where money is flowing: data connectivity, condition-specific AI, and cost-containment tools. Roadmaps that do not clearly reduce administrative or clinical spend will face tougher procurement cycles.

Headwinds

• Epic MyChart phishing exposes portal attack surface. A phishing campaign targeting Epic MyChart users shows patient portals are now prime entry points for credential theft and secondary fraud. For any organization running patient- or clinician-facing apps, security teams must assume that brand impersonation and session hijacking are active threats and that MFA, anomaly detection, and takedown processes are as critical as core EHR hardening.
• Cyberattack disrupts Boston Scientific operations. The cyberattack on Boston Scientific, with operational disruption, is a warning for all medtech and digital health firms that ransomware and supply chain attacks now carry direct patient safety and revenue risk. Device software, cloud services, and manufacturing systems need unified incident response planning, tested backups, and SBOM visibility to avoid multi-week outages.
• Fraud enforcement intensifies across payers and PBMs. Maryland’s lawsuit against UnitedHealth’s Optum unit over a faulty Medicaid system, the Florida AG’s price-fixing case against Express Scripts and Prime Therapeutics, and large Medicare fraud recoveries point to rising enforcement focus on billing, coding, and pricing systems. CTOs responsible for claims, risk adjustment, and pharmacy platforms should expect deeper audits of algorithms, rule engines, and data provenance.

Discussion: Treat security and compliance as first-order product requirements. Reassess portal security posture, ransomware playbooks, and auditability of billing and pricing logic before regulators or attackers force the issue.

Tailwinds

• AI signal interpretation framed as core opportunity. Commentary on “reading the body’s signals” with AI reflects growing acceptance that continuous data from wearables, implants, and virtual care can underpin new diagnostic and monitoring pathways. CTOs should see a clear opening for platforms that standardize ingestion of multi-modal physiologic data, apply explainable models, and feed structured outputs back into EHR workflows using FHIR Observation and Device resources.
• NCQA taps Komodo data for next-gen HEDIS. NCQA’s access to Komodo’s large-scale, AI-powered claims and encounter data for HEDIS research signals that quality measurement will shift toward more granular, longitudinal metrics. Vendors and provider organizations that can expose clean, standardized FHIR data and integrate evolving HEDIS definitions into analytics pipelines will be better positioned in value-based contracting and payer negotiations.
• Data connectivity tools gaining operational traction. Datavant’s push to shrink record retrieval times aligns with broader moves to reduce administrative friction cited by policy voices focused on affordability. Health IT teams that invest early in interoperable exchange, consent orchestration, and record location services can turn what is currently a cost center into a differentiating capability for payers, employers, and life sciences partners.

Discussion: Lean into opportunities where AI and interoperability meet measurable outcomes: quality metrics, remote monitoring, and data liquidity. Design platforms so that adding new data sources or quality measures becomes a configuration exercise, not a re-platforming.

Tech Implications

• Portal security and identity move to the forefront. The MyChart phishing campaign highlights gaps in user education, identity assurance, and session security for patient portals and mobile apps. Engineering teams should prioritize phishing-resistant MFA, device binding, OAuth scopes that follow least privilege, and anomaly detection for unusual access patterns, along with rapid takedown pipelines for spoofed domains.
• Interoperability stack maturity becomes competitive edge. Datavant’s retrieval claims and NCQA’s data-driven HEDIS work both depend on standardized, high-fidelity data exchange. Architectures that treat FHIR APIs, HL7 v2 integration, and record linkage as shared platform services, rather than bespoke per-integration projects, will scale better as partners demand near real-time access for quality, research, and payment integrity.
• AI platforms must be built for trust and evidence. Funding for AI behavioral health and broader commentary on AI’s role in reading physiologic signals will increase scrutiny on model validation, bias, and explainability. CTOs should treat MLOps, dataset governance, and post-market performance monitoring as core platform features, particularly if they anticipate FDA scrutiny for clinical decision support or digital therapeutics.

Discussion: Revisit your reference architecture with three lenses: identity and access for patients and clinicians, a shared interoperability layer for all data flows, and a governed AI platform that can withstand security, clinical, and regulatory review.

CTO Action Items

Run a cross-functional review of patient-facing portals and apps focused on phishing resistance, MFA adoption, and incident response, and close any obvious gaps before the next campaign hits. Ask your teams for a concrete plan to expose and consume FHIR APIs for record retrieval and quality reporting, including how you will integrate with third-party exchange networks over the next 12 to 24 months. For any AI in production or late-stage development, require clear documentation of training data, validation results across subpopulations, and monitoring plans that would satisfy both internal clinicians and a skeptical regulator. Finally, tie at least one major 2027 roadmap item directly to employer or payer cost pressures, and ensure your analytics can quantify its impact on total cost of care rather than only operational metrics.